This inventor holds 29 USPTO granted patents and 3 published patent applications, plus 8 CIPO patents and 21 EPO patents, primarily in Receptor Modulators. Top assignees: Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd. Active years: 2008-2026.
Location History:
- Rixheim, FR (2008)
- Dietwiller, FR (2010 - 2014)
- Allschwil, CH (2013 - 2024)
Company Filing History:
Years Active: 2008-2026
Areas of Expertise:
Title: **Sylvia Richard-Bildstein: A Leader in Pharmaceutical Innovations**
Introduction
Sylvia Richard-Bildstein, based in Allschwil, Switzerland, is a distinguished inventor with an impressive portfolio of 28 patents. Her work primarily focuses on the development of innovative pharmaceutical compounds, particularly in the field of receptor modulation, which has significant implications for cancer treatments and other health conditions.
Latest Patents
Among her most recent patents, Sylvia has introduced novel N-substituted indole derivatives that serve as PGE2 receptor modulators. This invention includes derivatives of a specific formula, along with their preparation methods, pharmaceutically acceptable salts, and applications in pharmaceuticals. These compounds hold promise for the modulation of prostaglandin 2 receptors, EP2 and EP4.
Additionally, she has patented pyrimidine derivatives that act as PGE2 receptor modulators. This invention aims at treating cancer by enhancing the immune response, particularly through reactivation of the immune system within the tumor. Moreover, Sylvia has developed new benzofurane and benzothiophene derivatives, further enriching her portfolio with compounds poised for pharmaceutical applications.
Career Highlights
Throughout her career, Sylvia Richard-Bildstein has made significant contributions to pharmaceutical development while working with leading companies. Notably, she has been associated with Actelion Pharmaceuticals Ltd and Idorsia Pharmaceuticals Ltd, where her innovative research has driven advancements in drug development.
Collaborations
Sylvia's collaborations with notable colleagues like Olivier Corminboeuf and Daniel Bur have further strengthened her inventive pursuits. Working alongside experienced professionals has allowed her to enhance her research efforts and contribute effectively to the field of pharmaceuticals.
Conclusion
Sylvia Richard-Bildstein exemplifies the spirit of innovation in pharmaceuticals with her substantial contributions and patent achievements. Her work continues to shape the future of drug development, particularly in cancer treatment, showcasing the essential role of inventors in advancing medical science.